Back to News
Market Impact: 0.12
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationCompany Fundamentals
Schall, Brown & Schwartz LLP reminded investors of an ongoing class action against Capricor Therapeutics (CAPR) alleging securities-law violations under §§10(b) and 20(a). The notice itself provides no new financial metrics or outcomes, but it reinforces litigation overhang that can weigh on sentiment and the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
CAPR-0.70
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Faraday Copper completes acquisition of BHP’s San Manuel project
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius